bay-k-8644 has been researched along with Atrioventricular Nodal Re-Entrant Tachycardia in 3 studies
3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester: A dihydropyridine derivative, which, in contrast to NIFEDIPINE, functions as a calcium channel agonist. The compound facilitates Ca2+ influx through partially activated voltage-dependent Ca2+ channels, thereby causing vasoconstrictor and positive inotropic effects. It is used primarily as a research tool.
Bay-K-8644 : A racemate comprising equimolar amounts of (R)- and (S)-Bay-K-8644
methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate : A pentasubstituted dihydropyridine carrying methoxycarbonyl, 2-(trifluoromethyl)phenyl and nitro substituents at positions 3, 4 and 5 respectively as well as two methyl substituents at positions 2 and 6.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Ranolazine is an antianginal agent shown to exert an antiarrhythmic effect in experimental models of long QT syndrome." | 3.74 | Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine. ( Antzelevitch, C; Belardinelli, L; Glass, A; Goodrow, RJ; Sicouri, S; Timothy, KW; Zygmunt, AC, 2007) |
| "We measured left ventricular monophasic action potentials in normal dogs and dogs with left ventricular hypertrophy before and after administration of the calcium agonist BAY K 8644 and the potassium channel blocker cesium." | 3.68 | Canine left ventricular hypertrophy predisposes to ventricular tachycardia induction by phase 2 early afterdepolarizations after administration of BAY K 8644. ( Ayers, GM; Ben-David, J; Pride, HP; Zipes, DP, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, Y | 1 |
| Jones, PP | 1 |
| Guo, J | 1 |
| Zhong, X | 1 |
| Clark, RB | 1 |
| Zhou, Q | 1 |
| Wang, R | 1 |
| Vallmitjana, A | 1 |
| Benitez, R | 1 |
| Hove-Madsen, L | 1 |
| Semeniuk, L | 1 |
| Guo, A | 1 |
| Song, LS | 1 |
| Duff, HJ | 1 |
| Chen, SR | 1 |
| Sicouri, S | 1 |
| Timothy, KW | 1 |
| Zygmunt, AC | 1 |
| Glass, A | 1 |
| Goodrow, RJ | 1 |
| Belardinelli, L | 1 |
| Antzelevitch, C | 1 |
| Ben-David, J | 1 |
| Zipes, DP | 1 |
| Ayers, GM | 1 |
| Pride, HP | 1 |
3 other studies available for bay-k-8644 and Atrioventricular Nodal Re-Entrant Tachycardia
| Article | Year |
|---|---|
Phospholamban knockout breaks arrhythmogenic Ca²⁺ waves and suppresses catecholaminergic polymorphic ventricular tachycardia in mice.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2013 |
Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2007 |
Canine left ventricular hypertrophy predisposes to ventricular tachycardia induction by phase 2 early afterdepolarizations after administration of BAY K 8644.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1992 |